Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002340604 | SCV002635797 | pathogenic | Diamond-Blackfan anemia | 2015-09-04 | criteria provided, single submitter | clinical testing | The p.Y16* pathogenic mutation (also known as c.48C>A), located in coding exon 2 of the RPL5 gene, results from a C to A substitution at nucleotide position 48. This changes the amino acid from a tyrosine to a stop codon within coding exon 2. This nonsense mutation was reportedly de novo in a male DBA patient with cleft palate, abnormal right thumb malformations, growth retardation, and steroid response (Boria I et al. Hum Mutat. 2010;31(12):1269-1279). A mutation (c.48C>G) resulting in the same amino acid change, was reported in a female DBA patient diagnosed at birth and who was responsive to high steroid doses and also received red blood cell transfusions. In the same study, another mutation (c.46_47insA) resulting in the same amino acid change was reported in a male DBA patient diagnosed at birth with micrognathia, hypertelorism, soft cleft palate, triphalangeal right thumb, widened webbed space between first and second toes, and hypospadias (Gazda HT et al. Am J Hum Genet. 2008;83(6):769-780). In addition to the clinical data presented in the literature, since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |